Neonc Technologies Holdings Inc (NTHI)

$12.00 -0.11 (-0.91%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 9,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, h...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 663 7831
Address:
23975 Park Sorrento, Suite 205, Calabasas, United States
NeOnc_Technologies
NeOnc_Technologies Jul. 13 at 7:46 AM
$NTHI What we’re building at NeOnc Technologies is focused on one of the hardest challenges in neuro-oncology: delivering therapies to the brain. Our two lead programs, NEO100™ and NEO212™, reflect that mission in different but complementary ways. NEO100 is our intranasal, non-invasive nose-to-brain delivery candidate being advanced for recurrent high-grade gliomas. NEO212 is our oral perillyl alcohol-temozolomide conjugate being developed for aggressive brain tumors. Recent UAE IND authorizations for both programs mark an important expansion of our international clinical development footprint, while NEO100 remains fully enrolled in its Phase 2a study, with top-line data expected by the end of July 2026. For patients facing devastating CNS cancers, the “why” is clear: better delivery, new treatment pathways, and continued progress toward addressing urgent unmet need. $NTHI #NeOnc #Biotech #DrugDelivery
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jul. 12 at 4:09 AM
$NTHI Watch: New to the Street TV Presents - NeOnc Receives Abu Dhabi IND Approval for Brain Cancer Drug NEO100 The approval expands NeOnc's global clinical development program alongside ongoing U.S. studies. The company's Phase 2a trial of NEO100 is already fully enrolled, with top-line results expected by the end of July. NEO100 has also received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations in the United States, supporting its continued regulatory development. #NeOnc #NTHI #BrainCancer #ClinicalTrials #Biotechnology #Innovation https://www.youtube.com/watch?v=SOD20zoi15Y
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jul. 7 at 8:10 AM
$NTHI Developing new therapies is only one part of the journey. Regulatory progress is what moves promising science closer to patients. NeOnc's recent UAE IND approvals for both NEO212 and NEO100 represent meaningful steps toward expanding clinical development beyond a single geography. NEO212 enters Phase 2 development after completing its Phase 1 dose-escalation study and identifying the recommended Phase 2 dose. Meanwhile, NEO100 has now received authorization supporting multiple clinical programs, including pediatric development, highlighting the broad potential of NeOnc's proprietary platform. Every regulatory milestone creates new opportunities to generate clinical data, collaborate with investigators, and accelerate the development of therapies for patients with limited treatment options. We're excited about what comes next. #NeOnc #NTHI #BrainCancer #ClinicalTrials #Biotechnology #Innovation #UAE
0 · Reply
focafoca99
focafoca99 Jul. 2 at 9:40 PM
$NTHI disclosed a board change as Dr. Chiang resigned and Nasim Shomali was elected director.
1 · Reply
Beroname
Beroname Jul. 2 at 6:07 PM
$NTHI is it good time to buy?
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jul. 1 at 5:52 PM
$NTHI In recent weeks, NeOnc announced UAE IND approvals for both NEO212 and NEO100, marking an important expansion of the Company's clinical development strategy. For NEO212, the authorization follows the successful completion of the Phase 1 dose-escalation study and enables Phase 2 clinical evaluation in the UAE. For NEO100, the approval extends across all three development programs, including adult Phase 1 through Phase 2 studies as well as pediatric clinical development. Together, these authorizations demonstrate continued regulatory momentum for NeOnc's pipeline while expanding opportunities to advance innovative therapies for patients with aggressive brain cancers. With discussions also continuing with the U.S. FDA and multiple clinical catalysts ahead, NeOnc remains focused on bringing novel treatment options to patients facing some of the most challenging CNS cancers. #NeOnc #NTHI #BrainCancer #ClinicalTrials #Biotechnology #Innovation
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 30 at 12:43 PM
$NTHI A quote from Amir Heshmatpour, CEO, Executive Chairman, and President of NeOnc Technologies, on the recent UAE approval for NEO100. #NeOnc #NTHI #BrainCancer #ClinicalTrials #Biotechnology #Innovation
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 25 at 1:55 PM
$NTHI We recently announced that NEO100 has received IND authorization from the Department of Health, Abu Dhabi. Why is the UAE authorization for NEO100 so significant? The authorization spans three clinical protocols, adult studies from Phase 1 through Phase 2, and includes a defined pediatric development pathway. This broad authorization is intended to support parallel development activities as NeOnc advances its intranasal delivery platform internationally. In the United States, NEO100 has already received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations. The NEO100-01 Phase 2a trial in recurrent IDH1-mutant high-grade glioma is fully enrolled, and NeOnc expects to report top-line data by the end of July 2026. The upcoming readout represents an important milestone in evaluating NEO100's potential as a non-invasive treatment approach for patients with recurrent high-grade gliomas. Read more: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-receives-uae-ind-approval-neo100-expanding
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 25 at 11:49 AM
$NTHI We recently announced that NEO100 has received IND authorization from the Department of Health, Abu Dhabi. Why is the UAE authorization for NEO100 so significant? The authorization spans three clinical protocols, adult studies from Phase 1 through Phase 2, and includes a defined pediatric development pathway. This broad authorization is intended to support parallel development activities as NeOnc advances its intranasal delivery platform internationally. In the United States, NEO100 has already received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations. The NEO100-01 Phase 2a trial in recurrent IDH1-mutant high-grade glioma is fully enrolled, and NeOnc expects to report top-line data by the end of July 2026. The upcoming readout represents an important milestone in evaluating NEO100's potential as a non-invasive treatment approach for patients with recurrent high-grade gliomas. Read more: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-receives-uae-ind-approval-neo100-expanding #NeOnc #NTHI #BrainCancer #Glioblastoma #Biotech
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 23 at 2:56 PM
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone $NTHI https://stocktwits.com/news/others/business/ne-onc-technologies-receives-uae-ind-approval-for-neo-100-expanding-global-development-ahead-of-anticipated-phase-2-data-milestone/cZKw3vaR7aj
0 · Reply
Latest News on NTHI
Wall Street is Watching These Biotechs

Jul 1, 2026, 9:32 AM EDT - 13 days ago

Wall Street is Watching These Biotechs

ELAB

NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum

Jun 24, 2026, 8:45 AM EDT - 20 days ago

NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

Jun 23, 2026, 9:00 AM EDT - 21 days ago

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

NeOnc Technologies Holdings Proxy statement: Proxy filing

Jun 23, 2026, 8:00 AM EDT - 21 days ago

NeOnc Technologies Holdings Proxy statement: Proxy filing

NeOnc Technologies Holdings Proxy statement: Proxy filing

Jun 23, 2026, 8:00 AM EDT - 21 days ago

NeOnc Technologies Holdings Proxy statement: Proxy filing

WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

Jun 22, 2026, 8:45 AM EDT - 22 days ago

WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212

Jun 17, 2026, 9:18 AM EDT - 27 days ago

NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212

Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND

Jun 16, 2026, 1:49 PM EDT - 27 days ago

Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

Jun 16, 2026, 9:00 AM EDT - 4 weeks ago

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

NeOnc Technologies files to sell 555,554 shares of common stock for holders

2026-06-15T20:31:23.000Z - 4 weeks ago

NeOnc Technologies files to sell 555,554 shares of common stock for holders

WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates

Jun 15, 2026, 8:35 AM EDT - 4 weeks ago

WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates

NeOnc Technologies Holdings Registration statement: Registration filing

Jun 15, 2026, 8:00 AM EDT - 4 weeks ago

NeOnc Technologies Holdings Registration statement: Registration filing

NeOnc Technologies Holdings Proxy statement: Proxy filing

Jun 11, 2026, 8:00 AM EDT - 4 weeks ago

NeOnc Technologies Holdings Proxy statement: Proxy filing

The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade

Jun 9, 2026, 8:45 AM EDT - 5 weeks ago

The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade

The Next Great AI Revolution May Be Drug Delivery

May 29, 2026, 9:05 AM EDT - 6 weeks ago

The Next Great AI Revolution May Be Drug Delivery

NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones

May 19, 2026, 10:28 AM EDT - 2 months ago

NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones

NeOnc Technologies initiated with a Buy at Alliance Global

2026-05-19T11:05:51.000Z - 2 months ago

NeOnc Technologies initiated with a Buy at Alliance Global

NeOnc Provides Business Update and Reports Q1 2026 Financial Results

May 18, 2026, 9:00 AM EDT - 2 months ago

NeOnc Provides Business Update and Reports Q1 2026 Financial Results

NeOnc Technologies initiated with a Buy at Maxim

2026-05-18T12:00:00.000Z - 2 months ago

NeOnc Technologies initiated with a Buy at Maxim

NeOnc Technologies Holdings Earnings release: Q1 2026

May 18, 2026, 7:00 AM EDT - 2 months ago

NeOnc Technologies Holdings Earnings release: Q1 2026

NeOnc Technologies Holdings Quarterly report: Q1 2026

May 18, 2026, 7:00 AM EDT - 2 months ago

NeOnc Technologies Holdings Quarterly report: Q1 2026

Biotech's Next Wave May Already be in Motion

May 7, 2026, 8:45 AM EDT - 2 months ago

Biotech's Next Wave May Already be in Motion

Where Executives Are Doubling Down on Their Companies' Fortunes

May 6, 2026, 8:35 AM EDT - 2 months ago

Where Executives Are Doubling Down on Their Companies' Fortunes

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

May 5, 2026, 9:00 AM EDT - 2 months ago

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

NeOnc Technologies initiated with a Buy at BTIG

2026-04-24T10:17:12.000Z - 2 months ago

NeOnc Technologies initiated with a Buy at BTIG

NeOnc Technologies files to sell 680,558 shares of common stock for holders

2026-04-10T21:20:42.000Z - 3 months ago

NeOnc Technologies files to sell 680,558 shares of common stock for holders

NeOnc Technologies Holdings Registration statement: Registration filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

NeOnc Technologies files $300M mixed securities shelf

2026-04-02T17:07:18.000Z - 3 months ago

NeOnc Technologies files $300M mixed securities shelf

NeOnc Technologies Holdings Registration statement: Registration filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

Apr 1, 2026, 9:00 AM EDT - 3 months ago

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

NeOnc Technologies Holdings Earnings release: Q4 2025

Apr 1, 2026, 7:00 AM EDT - 3 months ago

NeOnc Technologies Holdings Earnings release: Q4 2025

NeOnc Technologies Holdings Annual report: Q4 2025

Apr 1, 2026, 7:00 AM EDT - 3 months ago

NeOnc Technologies Holdings Annual report: Q4 2025

NeOnc Technologies appoints Choi as Chief Accounting Officer

2026-03-13T13:05:36.000Z - 4 months ago

NeOnc Technologies appoints Choi as Chief Accounting Officer

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Mar 13, 2026, 9:00 AM EDT - 4 months ago

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Mar 12, 2026, 8:52 AM EDT - 4 months ago

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies reports Phase 1 dose-escalation results for NEO212

2026-03-04T13:06:31.000Z - 4 months ago

NeOnc Technologies reports Phase 1 dose-escalation results for NEO212

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

Mar 4, 2026, 8:00 AM EST - 4 months ago

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

MRK

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

Feb 27, 2026, 9:00 AM EST - 4 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

NeOnc Technologies files to sell 2.95M shares of common stock for holders

2026-02-06T21:55:14.000Z - 5 months ago

NeOnc Technologies files to sell 2.95M shares of common stock for holders

NeOnc Technologies Holdings Registration statement: Registration filing

Feb 6, 2026, 7:00 AM EST - 5 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

NeOnc Technologies secures strategic PIPE investment from Cinctive Capital

2026-01-30T14:17:11.000Z - 5 months ago

NeOnc Technologies secures strategic PIPE investment from Cinctive Capital

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Jan 30, 2026, 9:00 AM EST - 5 months ago

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Jan 9, 2026, 7:32 PM EST - 6 months ago

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies announces updated NEO100 clinical results

2025-12-15T14:16:09.000Z - 7 months ago

NeOnc Technologies announces updated NEO100 clinical results

NeOnc Technologies Reports Updated Clinical Results

Dec 15, 2025, 9:00 AM EST - 7 months ago

NeOnc Technologies Reports Updated Clinical Results

NeOnc Technologies files to sell 111.7K shares of common stock for holders

2025-12-15T13:00:48.000Z - 7 months ago

NeOnc Technologies files to sell 111.7K shares of common stock for holders

NeOnc Technologies Holdings Registration statement: Registration filing

Dec 15, 2025, 7:00 AM EST - 7 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

NeOnc Technologies announces preclinical findings from USC collaboration

2025-12-01T14:10:42.000Z - 8 months ago

NeOnc Technologies announces preclinical findings from USC collaboration

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

Dec 1, 2025, 9:00 AM EST - 8 months ago

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

NeOnc Technologies Holdings Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

NeOnc Technologies Holdings Earnings release: Q3 2025

NeOnc Technologies Holdings Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

NeOnc Technologies Holdings Quarterly report: Q3 2025

NeOnc Technologies completes full patient enrollment in NEO100-1 Phase 2a trial

2025-11-13T14:16:23.000Z - 8 months ago

NeOnc Technologies completes full patient enrollment in NEO100-1 Phase 2a trial

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

Nov 13, 2025, 9:00 AM EST - 8 months ago

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

NeOnc announces updated results Phase 1/2a, compassionate care studies

2025-11-12T13:26:29.000Z - 8 months ago

NeOnc announces updated results Phase 1/2a, compassionate care studies

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

Nov 7, 2025, 9:00 AM EST - 8 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

NeOnc Technologies appoints Heshmatpour as Chief Executive Officer

2025-11-04T14:05:59.000Z - 9 months ago

NeOnc Technologies appoints Heshmatpour as Chief Executive Officer

NeOnc says Sheikh Nahyan bin Zayed Al Nahyan assumes NuroMENA chairmanship

2025-10-28T13:10:14.000Z - 9 months ago

NeOnc says Sheikh Nahyan bin Zayed Al Nahyan assumes NuroMENA chairmanship

NeOnc Technologies’ NuroMENA signs master services agreement with M42’s IROS

2025-10-09T13:10:30.000Z - 9 months ago

NeOnc Technologies’ NuroMENA signs master services agreement with M42’s IROS

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Oct 9, 2025, 9:00 AM EDT - 9 months ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

NeOnc Technologies, Quazar Investment to close $50M partnership by Oct. 23

2025-10-06T13:10:28.000Z - 10 months ago

NeOnc Technologies, Quazar Investment to close $50M partnership by Oct. 23

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Sep 29, 2025, 9:00 AM EDT - 10 months ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

Sep 10, 2025, 9:40 AM EDT - 10 months ago

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

BGL

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

Sep 10, 2025, 9:00 AM EDT - 10 months ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

Aug 25, 2025, 9:00 AM EDT - 11 months ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

NeOnc Technologies Holdings Earnings release: Q2 2025

Aug 19, 2025, 7:00 AM EDT - 11 months ago

NeOnc Technologies Holdings Earnings release: Q2 2025

NeOnc Technologies Holdings Quarterly report: Q2 2025

Aug 19, 2025, 7:00 AM EDT - 11 months ago

NeOnc Technologies Holdings Quarterly report: Q2 2025

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Aug 11, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

Aug 7, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

Aug 4, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

Jul 30, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

Jul 23, 2025, 10:53 AM EDT - 1 year ago

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

Jul 8, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

Jun 6, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

NeOnc Technologies Holdings Registration statement: Registration filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

NeOnc Technologies Holdings Registration statement: Registration filing

NeOnc Technologies Holdings Quarterly report: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

NeOnc Technologies Holdings Quarterly report: Q1 2025

NeOnc Technologies Holdings Registration statement: Registration filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

NeOnc Technologies Holdings Registration statement: Registration filing

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

Apr 15, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

Apr 14, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

Apr 10, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

Apr 8, 2025, 4:05 PM EDT - 1 year ago

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Mar 31, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

Mar 27, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

Mar 25, 2025, 8:45 AM EDT - 1 year ago

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

Mar 25, 2025, 8:15 AM EDT - 1 year ago

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

NeOnc Technologies Holdings Registration statement: Registration filing

Feb 26, 2025, 7:00 AM EST - 1 year ago

NeOnc Technologies Holdings Registration statement: Registration filing

NeOnc Technologies Holdings Registration statement: Registration filing

Jan 31, 2025, 7:00 AM EST - 1 year ago

NeOnc Technologies Holdings Registration statement: Registration filing

NeOnc Technologies Holdings Registration statement: Registration filing

Jan 3, 2025, 7:00 AM EST - 1 year ago

NeOnc Technologies Holdings Registration statement: Registration filing

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

Oct 7, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

Aug 5, 2024, 11:00 AM EDT - 2 years ago

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

Jul 16, 2024, 11:15 AM EDT - 2 years ago

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

Jun 26, 2024, 4:39 PM EDT - 2 years ago

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

NeOnc_Technologies
NeOnc_Technologies Jul. 13 at 7:46 AM
$NTHI What we’re building at NeOnc Technologies is focused on one of the hardest challenges in neuro-oncology: delivering therapies to the brain. Our two lead programs, NEO100™ and NEO212™, reflect that mission in different but complementary ways. NEO100 is our intranasal, non-invasive nose-to-brain delivery candidate being advanced for recurrent high-grade gliomas. NEO212 is our oral perillyl alcohol-temozolomide conjugate being developed for aggressive brain tumors. Recent UAE IND authorizations for both programs mark an important expansion of our international clinical development footprint, while NEO100 remains fully enrolled in its Phase 2a study, with top-line data expected by the end of July 2026. For patients facing devastating CNS cancers, the “why” is clear: better delivery, new treatment pathways, and continued progress toward addressing urgent unmet need. $NTHI #NeOnc #Biotech #DrugDelivery
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jul. 12 at 4:09 AM
$NTHI Watch: New to the Street TV Presents - NeOnc Receives Abu Dhabi IND Approval for Brain Cancer Drug NEO100 The approval expands NeOnc's global clinical development program alongside ongoing U.S. studies. The company's Phase 2a trial of NEO100 is already fully enrolled, with top-line results expected by the end of July. NEO100 has also received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations in the United States, supporting its continued regulatory development. #NeOnc #NTHI #BrainCancer #ClinicalTrials #Biotechnology #Innovation https://www.youtube.com/watch?v=SOD20zoi15Y
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jul. 7 at 8:10 AM
$NTHI Developing new therapies is only one part of the journey. Regulatory progress is what moves promising science closer to patients. NeOnc's recent UAE IND approvals for both NEO212 and NEO100 represent meaningful steps toward expanding clinical development beyond a single geography. NEO212 enters Phase 2 development after completing its Phase 1 dose-escalation study and identifying the recommended Phase 2 dose. Meanwhile, NEO100 has now received authorization supporting multiple clinical programs, including pediatric development, highlighting the broad potential of NeOnc's proprietary platform. Every regulatory milestone creates new opportunities to generate clinical data, collaborate with investigators, and accelerate the development of therapies for patients with limited treatment options. We're excited about what comes next. #NeOnc #NTHI #BrainCancer #ClinicalTrials #Biotechnology #Innovation #UAE
0 · Reply
focafoca99
focafoca99 Jul. 2 at 9:40 PM
$NTHI disclosed a board change as Dr. Chiang resigned and Nasim Shomali was elected director.
1 · Reply
Beroname
Beroname Jul. 2 at 6:07 PM
$NTHI is it good time to buy?
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jul. 1 at 5:52 PM
$NTHI In recent weeks, NeOnc announced UAE IND approvals for both NEO212 and NEO100, marking an important expansion of the Company's clinical development strategy. For NEO212, the authorization follows the successful completion of the Phase 1 dose-escalation study and enables Phase 2 clinical evaluation in the UAE. For NEO100, the approval extends across all three development programs, including adult Phase 1 through Phase 2 studies as well as pediatric clinical development. Together, these authorizations demonstrate continued regulatory momentum for NeOnc's pipeline while expanding opportunities to advance innovative therapies for patients with aggressive brain cancers. With discussions also continuing with the U.S. FDA and multiple clinical catalysts ahead, NeOnc remains focused on bringing novel treatment options to patients facing some of the most challenging CNS cancers. #NeOnc #NTHI #BrainCancer #ClinicalTrials #Biotechnology #Innovation
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 30 at 12:43 PM
$NTHI A quote from Amir Heshmatpour, CEO, Executive Chairman, and President of NeOnc Technologies, on the recent UAE approval for NEO100. #NeOnc #NTHI #BrainCancer #ClinicalTrials #Biotechnology #Innovation
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 25 at 1:55 PM
$NTHI We recently announced that NEO100 has received IND authorization from the Department of Health, Abu Dhabi. Why is the UAE authorization for NEO100 so significant? The authorization spans three clinical protocols, adult studies from Phase 1 through Phase 2, and includes a defined pediatric development pathway. This broad authorization is intended to support parallel development activities as NeOnc advances its intranasal delivery platform internationally. In the United States, NEO100 has already received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations. The NEO100-01 Phase 2a trial in recurrent IDH1-mutant high-grade glioma is fully enrolled, and NeOnc expects to report top-line data by the end of July 2026. The upcoming readout represents an important milestone in evaluating NEO100's potential as a non-invasive treatment approach for patients with recurrent high-grade gliomas. Read more: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-receives-uae-ind-approval-neo100-expanding
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 25 at 11:49 AM
$NTHI We recently announced that NEO100 has received IND authorization from the Department of Health, Abu Dhabi. Why is the UAE authorization for NEO100 so significant? The authorization spans three clinical protocols, adult studies from Phase 1 through Phase 2, and includes a defined pediatric development pathway. This broad authorization is intended to support parallel development activities as NeOnc advances its intranasal delivery platform internationally. In the United States, NEO100 has already received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations. The NEO100-01 Phase 2a trial in recurrent IDH1-mutant high-grade glioma is fully enrolled, and NeOnc expects to report top-line data by the end of July 2026. The upcoming readout represents an important milestone in evaluating NEO100's potential as a non-invasive treatment approach for patients with recurrent high-grade gliomas. Read more: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-receives-uae-ind-approval-neo100-expanding #NeOnc #NTHI #BrainCancer #Glioblastoma #Biotech
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 23 at 2:56 PM
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone $NTHI https://stocktwits.com/news/others/business/ne-onc-technologies-receives-uae-ind-approval-for-neo-100-expanding-global-development-ahead-of-anticipated-phase-2-data-milestone/cZKw3vaR7aj
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 23 at 2:21 PM
$NTHI NeOnc Technologies is pleased to announce that NEO100 has received Investigational New Drug (IND) authorization from the Department of Health, Abu Dhabi. Key highlights include: • Authorization covers all three NEO100 clinical programs: NEO100-01, NEO100-02, and NEO100-03 • Includes Phase 1 through Phase 2 studies in adults • Establishes a pathway for pediatric studies pending further protocol review • Expands NeOnc's clinical development footprint in the UAE following the recent NEO212 IND authorization NEO100 is our lead clinical candidate, designed for non-invasive nose-to-brain delivery for patients with aggressive brain cancers. With top-line Phase 2a data expected by the end of July, we believe the program is approaching a pivotal stage in its clinical development. Read more: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-receives-uae-ind-approval-neo100-expanding #NeOnc #NTHI #BrainCancer #Glioblastoma #Biotech #ClinicalTrials
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 23 at 1:00 PM
$NTHI NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
0 · Reply
focafoca99
focafoca99 Jun. 22 at 2:11 PM
$NTHI benefited from Abu Dhabi IND authorization for NEO212, giving the biotech another development path.
0 · Reply
newsfile_corp
newsfile_corp Jun. 22 at 12:45 PM
https://nfne.ws/302323 $NTHI @wstprnews #BBIO #BIIB #BMY #LLY #NTHI #Advertising #Publishing #NASDAQ #Investing
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 22 at 8:58 AM
$NTHI A quote from Amir Heshmatpour, CEO, Executive Chairman, and President of NeOnc Technologies, on the recent UAE IND approval for NEO212. #NeOnc #NTHI #BrainCancer #Biotech #ClinicalTrials #UAE #AbuDhabi
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 18 at 6:17 AM
$NTHI NeOnc Technologies is proud to announce that we’ve secured UAE IND approval for NEO212 following successful Phase 1 completion, advancing toward global Phase 2 development. • Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol temozolomide conjugate, in the United Arab Emirates • Follows completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose • Adds an international clinical pathway alongside continuing U.S. FDA discussions on a potential registrational pathway for NEO212 Read more about this exciting news here: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-secures-uae-ind-approval-neo212-following
0 · Reply
focafoca99
focafoca99 Jun. 17 at 2:41 PM
$NTHI got IND approval in Abu Dhabi for its oral brain‑tumor therapy NEO212.
0 · Reply
BioRich
BioRich Jun. 17 at 11:32 AM
$XBI Nice article on some emerging opportunities from a breadth of sectors. Worth a read and look. My favorite is $SABS but haven't really had much exposure to the others. Anyone have a pros/cons on the others? $CUPR $HYFT $NTHI RGNT GELS? Why Traders Are Piling into These Emerging Healthcare Names as New Catalysts Emerge https://stocktwits.com/news-articles///null/cZKfn9YbbdUg3
2 · Reply
STACKD0E
STACKD0E Jun. 17 at 2:00 AM
$MCRP $CRE $NTHI
0 · Reply
focafoca99
focafoca99 Jun. 16 at 6:19 PM
$NTHI snags Abu Dhabi IND approval for NEO212, giving the brain-cancer drug an international development path.
0 · Reply
focafoca99
focafoca99 Jun. 16 at 5:21 PM
$NTHI progressed with its first international IND clearance for NEO212 in the UAE, paving the way for Phase 2 development.
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 16 at 2:03 PM
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development $NTHI https://stocktwits.com/news/others/business/ne-onc-technologies-secures-uae-ind-approval-for-neo-212-following-successful-phase-1-completion-advancing-toward-global-phase-2-development/cZKWr01R74c
0 · Reply